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Summary Cutaneous zygomycosis is the third most common form of zygomycosis.
However, scalp involvement is rare for this disease. In this study, we present a casezygomycosis;
Zygomycosis;
Scalp
of acute zygomycosis in a diabetic patient who was effectively treated with local
debridement, amphotericin B lipid complex and posaconazole.
© 2015 Published by Elsevier Limited on behalf of King Saud Bin Abdulaziz University
for Health Sciences.
m
m
C
A
c
p
w
tntroduction
he incidence of invasive zygomycosis has been
ncreasing over the past two decades [1—4]; this is
ost likely secondary to the increasing prevalence
f diabetes mellitus and high risk immunocom-
romised patients [4]. Cutaneous zygomycosis is
he third most common form of zygomycosis (19%)
5], and it can be superﬁcial, locally invasive or
isseminated primarily from the skin to other non-
ontiguous organs or, rarely, from other organs to
he skin [5,6]. Upper and lower extremities are
ommon sites of involvement, although any area of
he skin can be affected by zygomycosis [4]. How-
ver, scalp involvement is rare [4,7—10].
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876-0341/© 2015 Published by Elsevier Limited on behalf of King SaIn this study, we present a case of scalp
ucormycosis linked to use of a local herbal treat-
ent.
ase report
76-year-old Saudi male with a history of poorly
ontrolled diabetes, hypertension and blindness
resented with a 5-day history of a black scalp
ound associated with localized pain and pruri-
us. He had previously applied an herbal medication
o a small trauma-induced laceration on the scalp
aused by a falling object at home. He had no
istory of fever, headache or change in level of
onsciousness and no new neurological symptoms.
On examination, he was afebrile with sta-
le vital signs. Multiple erythematous indurated
ud Bin Abdulaziz University for Health Sciences.
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red and indurated and then progresses to a blackFigure 1 Day 0 at presentation.
plaques with overlying pustules were present on
the scalp. Several well-demarcated ulcers with
overlying black eschars, with the largest mea-
suring 6 cm× 4 cm and the smallest measuring
0.5 cm× 0.5 cm, were also presented (Fig. 1). The
initial wound culture grew both gram-positive and
gram-negative bacteria. His blood culture was neg-
ative for bacteria.
His white cell count was 17.7× 109 per liter
(L), with 79% neutrophils, 17 g/dL hemoglobin and
345× 109/L platelets. BUN was 5.6mmol/L, creat-
inine was 61mol/L, CO2 was 19mmol/L and RBS
was 16.8mmol/L. The results of his liver function
tests were normal. His last HbA1c was 13%.
His initial antibiotic treatment was 1 g IV
cefepime Q12H. The AFB smear was negative. He
did not improve clinically after 5 days (see Fig. 2).
He had increased erythema and induration over
his scalp wound but, otherwise, remained afebrile.
A head CT did not show any signs of bone inva-
sion or intracranial extension. Tissue culture and
histopathology results conﬁrmed a diagnosis of
mucormycosis (Rhizopus species) (Figs. 2 and 3).
He was treated with surgical debridement and
5mg/kg IV lipid complex amphotericin B lipid com-
plex daily for 1 month, followed by posaconazole
for 3 months. The patient’s lesions completely
resolved.
DiscussionZygomycosis was ﬁrst described as a cause of
human disease in 1885, and the ﬁrst cutaneous case
e
t
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as reported in 1929 [10]. Cutaneous zygomycosis
s the third most common form of zygomyco-
is (11—19%) following rhinocerebral (39%) and
ulmonary disease (24%) [4—6]. Unlike other pre-
entations of mucormycosis, 40—50% of patients
ith cutaneous zygomycosis are immunocompetent
4,5,11]. Trauma is the most common predisposing
actor for cutaneous zygomycosis, especially when
ssociated with soiling.
Risk factors for cutaneous zygomycosis include
ncontrolled diabetes, diabetic ketoacidosis,
urns, chronic renal failure solid organ trans-
lants, hematological malignancies, neutropenia,
teroid use, prolonged use of voriconazole and
eferoxamine and low birth weight [4,7,11—14].
Cutaneous zygomycosis can present as a local-
zed, deep or disseminated disease [4]. Almost
alf of patients with cutaneous zygomycosis have
heir disease conﬁned to cutaneous and subcuta-
eous tissues, while the disease may extend to
eeper tissues, such as bones, tendons and mus-
les in 24% of cases. Disseminated disease is deﬁned
s hematogenous spread of zygomycetes from the
kin to other noncontiguous organs (20%) or from
ther organs to the skin (3%) [4,5]. Fungal elements
re isolated from multiple noncontagious sites [5].
lood cultures are rarely positive.
Direct inoculation of the skin after penetrating
rauma, surgery, burns, motor vehicle accidents,
alls and insect bites is the usual port of entry
or this disease [6]. Contact with soils or vegeta-
ion containing zygomycetes increases the chance
f acquiring the disease [15]. In our patient, it was
ot possible to determine if the primary trauma
o the scalp or a secondary infection caused by
he use of a contaminated herbal treatment caused
he patient’s disease. Contamination of such herbal
roducts has been previously documented [16,17].
Cutaneous zygomycosis can also be hospital-
cquired [18]. Risk factors in the hospital include
ontaminated venous access, types of adhesives
sed, occlusive dressings, burn wounds and post-
perative wounds. Sites of cutaneous zygomycosis
ormation described in the literature include intra-
uscular injection, insulin injection and catheter
nsertion sites [19—22].
The onset of cutaneous zygomycosis can be
radual and slowly progressing or aggressive and
ulminant [4,23], and its clinical presentation is
etermined by the immunity of the host, the
irulence of the fungi and the timing of diag-
osis and intervention. The skin lesion appearsschar and large ulcers. It can progress to necro-
izing fasciitis and extend to deeper tissues if
eft untreated [24,25]. In cases of disseminated
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sigure 2 Day 5 treatment with ceﬁpime. (A) H&E stain.
lassical nonseptated ribbon-like hyphae with wide-angle
isease in an immunosuppressed host, skin lesions
ay present as a nonspeciﬁc erythematous macule
26]. While Rhizopus is the most commonly iso-
ated genus of all zygomycosis infections across all
ites, Apophysomyces, Saksenaea and Mucor genera
re more common in cases of cutaneous or wound
ygomycosis [27].
Mortality varies depending on the clinical form
f zygomycosis; estimates range from 10% for
ocalized disease to 94% for disseminated disease.
ecrotizing fasciitis in cutaneous mucormycosis has
igh mortality [5,6].
Early diagnosis and treatment is important tomprove patient outcomes. The two main meth-
ds of diagnosis are isolation of zygomycetes by
ulture and histopathological examination. Biop-
ies should be taken from the center of the lesion,
p
o
e
tGMS (Gomori’s methenamine silver stain). They showed
nching.
specially from the black eschar and subcuta-
eous fat because zygomycetes frequently invade
lood vessels. In the histopathological analysis,
ocal areas of infection, such as nodules, extensive
ecrosis and hemorrhages with abscess formation
re frequently observed. Peripheral tissue invasion
y hyphal elements are easily identiﬁed, and this
dentiﬁcation is necessary for diagnosis [27].
Treatment of cutaneous zygomycosis includes a
ombination of aggressive surgical debridement,
ffective antifungal therapy and resolution of
nderlying risk factors. Angioinvasion, thrombo-
is, and extensive tissue necrosis result in poor
enetration of anti-infective agents to the site
f the infection, unless effective, aggressive and
arly surgical debridement is performed. A mor-
ality rate of less than 10% has been reported for
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Figure 3 Photomicrograph of Rhizopus species. Note the rhizoid structure at the end, characterizing Rhizopus from
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patients with cutaneous mucormycosis after treat-
ment with aggressive debridement and adjunct
antifungal therapy [5].
The ﬁrst-line antifungal agent for the treat-
ment of all forms of mucormycosis is a high dose
(10—15mg/kg/day) of liposomal amphotericin B
[6,28]. Treatment with liposomal amphotericin was
associated with a 67% survival rate compared to
a 39% survival with amphotericin B deoxycholate
treatment [6]. However, the pharmacokinetics of
amphotericin B lipid complex are different from
those of liposomal amphotericin B and, thus, it can-
not be considered an equal alternative treatment
for mucormycosis, especially for central nervous
system mucormycosis. Liposomal amphotericin B
penetrates the brain parenchyma more efﬁciently.
Even at a high dose of 30mg/kg/day, amphotericin
B lipid complex did not improve survival in a murine
model of disseminated zygomycosis compared to
liposomal amphotericin [6].
The pharmacological property differences
between polyenes are less likely to be important in
the treatment of non-disseminated cutaneous dis-
eases and in cases with a non-immunocompromised
host, when aggressive source control is performed
[28]. Our patient was adequately treated with
amphotericin B lipid complex, and this agent was
used because it was available on our formulary list.
Among azoles, posaconazole and ravucona-
zole have in vitro activity against mucormycosis.
Posaconazole has been used as a salvage therapy
for refractory mucormycosis, including for cases
that failed amphotericin treatment [29,30]. Mica-
fungin, a recently introduced echinocandin, may
E
Nave a future role in the treatment of mucormycosis
n combination with amphotericin and as a salvage
reatment for a failing regimen [31].
Hyperbaric oxygen (HBO) has been used as
n adjunctive therapeutic modality in rhinocere-
ral and soft tissue zygomycosis since 1970 [32].
BO inhibits fungal growth, promotes the oxida-
ive action of amphotericin B and improves tissue
ealing. In a review of 28 published cases of
ygomycosis, adjunctive HBO therapy was more
eneﬁcial in patients with modiﬁable immune sup-
ression, such as patients with zygomycosis due to
iabetes and trauma, compared to patients with
ematological malignancies [32].
Other adjunctive therapies that have been used
n case reports include interferon gamma and
olony-stimulating factor, which both increase the
bility of phagocytes to kill agents of mucormycosis
n vitro [6].
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